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Abstract
Background: Langerhans cells (LCs) are antigen-presenting dendritic cells located in the skin. It has been reported
that LC activation is associated with painful diabetic neuropathy (PDN); however, the mechanism of LC activation is
still unclear.
Methods: The db/db mouse, a rodent model of PDN, was used to study the roles of LCs in the development of
PDN in type 2 diabetes. Hind foot pads from db/db and control db/+ mice from 5 to 24 weeks of age
(encompassing the period of mechanical allodynia development and its abatement) were collected and processed
for immunohistochemistry studies. LCs were identified with immunohistochemistry using an antibody against
CD207 (Langerin). The intraepidermal nerve fibers and subepidermal nerve plexus were identified by
immunohistochemistry of protein gene product 9.5 (PGP 9.5) and tropomyosin-receptor kinase (Trk) A, the high
affinity nerve growth factor receptor.
Results: CD207-positive LCs increased in the db/db mouse during the period of mechanical allodynia, from 8 to
10 weeks of age, in both the epidermis and subepidermal plexus. At 16 weeks of age, when mechanical allodynia
diminishes, LC populations were reduced in the epidermis and subepidermal plexus. Epidermal LCs (ELCs) were
positive for Trk A. Subepidermal LCs (SLCs) were positive for CD68, suggesting that they are immature LCs.
Additionally, these SLCs were positive for the receptor of advanced glycation end products (RAGE) and were in
direct contact with TNF-α-positive nerve fibers in the subepidermal nerve plexus during the period of mechanical
allodynia. Intrathecal administration of SB203580, a p38 kinase inhibitor, significantly reduced mechanical allodynia,
TNF-α expression in the subepidermal plexus, and increased both ELC and SLC populations during the period of
mechanical allodynia.
Conclusions: Our data support the hypothesis that increased LC populations in PDN are activated by p38-dependent
neurogenic factors and may be involved in the pathogenesis of PDN.
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Background
Diabetes is a prevalent illness worldwide and it has been
estimated that 4.4% (330 million) of the world popula-
tion will be affected by 2030 [1]. The majority of diabetic
patients (>90%) have type 2 diabetes, which is tightly
linked to obesity and insulin insensitivity. Diabetic neu-
ropathy (DN) is the most common diabetic complication
that affects at least 50% of patients with either type 1 or
type 2 diabetes [2,3]. At least 40% to 50% of patients
with DN develop painful diabetic neuropathy (PDN),
which presents as abnormal sensory symptoms including
allodynia (increased sensitivity to innocuous stimuli),
hyperalgesia (exaggerated response to noxious stimuli),
and/or spontaneous pain [4,5]. Although there are mul-
tiple presentations of PDN in diabetic patients, the most
common symptoms of PDN result from a length-
dependent polyneuropathy that is associated with dam-
age of peripheral nerve endings in the skin [6]. Despite
increased animal and human research over the last two
decades, our understanding of the distal nerve pathology
that contributes to the development of PDN remains
limited. Current PDN treatments, such as anticonvulsants,
antidepressants and α2δ calcium channel antagonists, do
not target the pathomechanisms that are specific for PDN.
Therefore, only less than 30% of patients obtain satisfac-
tory pain relief [7].
Accumulating evidence suggests that inflammatory
mechanisms are essential for the development of compli-
cations in type 2 diabetes [8-12]. These mechanisms in-
volve increased levels of proinflammatory cytokines and
chemokines, as well as activation of inflammatory cells in-
cluding macrophages, T/B lymphocytes, and dendritic
cells [8,13-15]. However, it is unclear if these inflammatory
phenomena are involved in the pathogenesis of PDN from
type 2 diabetes. Here, we use db/db mice, a model for type
2 diabetes, to study the role of skin inflammation that
could contribute to peripheral nerve damage and pain
during the period of mechanical allodynia in db/db mice
from 6 to 12 weeks of age [16]. In this period, we detected
nerve growth factor (NGF)/p38-dependent upregulation
of inflammatory markers, including TNF-α, nitric oxide
synthases and cyclooxygenase (COX) 2, in db/db mice
[17]. Our findings suggested that there is increased in-
flammation in the peripheral nerves in db/db mice during
the period of mechanical allodynia.
Langerhans cells (LCs) are dendritic cells in the skin
which regulate local immune reactions [18]. LCs are de-
rived from monocytes that migrate to the dermis from
bone marrow during development [19,20]. In conditions
of skin infection or inflammation, CD68-positive LC pre-
cursors in the dermis proliferate and differentiate into
CD207-positive mature LCs in the epidermis, where they
serve as antigen-presenting cells to uptake pathogens
and activate T cells [19,21]. It has been reported that
increased LC numbers in the skin correlate with PDN in
both animal and human studies [22,23].
In the current study, we hypothesize that LCs are acti-
vated in the skin of db/db mice in response to increased
levels of neurogenic inflammatory markers in order to me-
diate mechanical allodynia. We examined the epidermal
CD207-positive/CD68-negative LCs and subepidermal
CD207-positive/CD68-positive LCs in the hind foot pads
of db/db and control db/+ mice. Our results provide evi-
dence that inhibition of NGF/p38 signaling in peripheral
nerves could prevent LC-mediated immune activation in
skin, and serve as a potential treatment for PDN.
Methods
Animals
Male C57BLKS db/db mice were purchased from The
Jackson Laboratory (stock number 000662, Bar Harbor,
ME, USA). The homozygous (Leprdb/Leprdb, or db/db)
mouse was used as a model of type 2 diabetes, while the
heterozygous mouse (Leprdb/+, or db/+) served as the
nondiabetic control. Analyses and procedures were per-
formed in compliance with protocols established by the
Animal Models of Diabetic Complications Consortium
(AMDCC), and approved by the University Committee on
Use and Care of Animals (UCUCA) at the University of
Michigan. All possible efforts were made to minimize the
animals’ suffering and the number of animals used.
Immunohistochemistry
Hind foot pads were collected, immersed for 6 to 8 hours
at 4°C in Zamboni’s fixative (2% paraformaldehyde, 0.2%
picric acid in 0.1 M phosphate buffer), rinsed in 30%
sucrose in PBS solution overnight, cryoembedded in
mounting media (optimal cutting temperature (OCT)
compound), and sectioned at 30 μm thick before being
processed for immunohistochemistry.
Tissue sections were processed for CD68, CD207, pro-
tein gene product 9.5 (PGP 9.5), tropomyosin-receptor
kinase (Trk) A, the receptor for advanced glycation end
products (RAGE), and TNF-α immunohistochemistry.
Sections were incubated at room temperature for 16 to
24 hours with primary antibodies: CD68 (1:200, LifeSpan
BioSciences, Seattle, WA, USA), CD207 (1:1000, Abcam
Biochemicals, Cambridge, MA, USA), PGP 9.5 (1:2000,
Millipore, Billerica, MA, USA), Trk A (1:500, R&D Sys-
tems, Minneapolis, MN, USA), RAGE (1:500, Santa Cruz
Biotechnology, Santa Cruz, CA, USA), and TNF-α
(1:500, Abcam Biochemicals). Sections were then rinsed
three times in PBS and incubated with secondary anti-
serum conjugated with different fluorophores (Alexa
Fluor 488, 594, or 647, Invitrogen, Carlsbad, CA, USA).
Sections were rinsed and mounted with ProLong Gold
Antifade Reagent (Invitrogen). In order to confirm that
there were no nonspecific immunoreactions, additional
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sections were incubated with primary or secondary anti-
sera alone. Fluorescent images were collected on an
Olympus FluoView 500 (Center Valley, PA, USA) con-
focal microscope using a 40 × 1.2 oil immersion object-
ive at a resolution of 1024 × 1024 pixels. The optical
section thickness was 0.5 μm. Approximately 40 images
per stack were flattened using the MetaMorph (version
6.14, Molecular Devices, Sunnyvale, CA, USA) arith-
metic option. Six sections were measured for each foot
pad. Cell density data were presented as the mean num-
ber of cells per linear millimeter of epidermis from a
total of 12 sections per animal.
SB203580 treatment
An osmotic minipump (ALZET model 1007D, DURECT
Corporation, Cupertino, CA, USA) was used for con-
tinuous intrathecal infusion into the lumbar spinal cord
region. The 100 μl volume minipump is designed with a
0.51 μl/h infusion rate. The minipumps were filled with
artificial cerebrospinal fluid (CSF) that contained 10%
dimethyl sulfoxide (DMSO) with or without SB203580
(1 mg/ml, EMD Chemicals, Gibbstown, NJ, USA), a p38
kinase inhibitor. The minipumps were implanted into
the dorsal subcutaneous space between the shoulder
blades of each mouse at 7 weeks of age under sterile
conditions. A caudally directed polyethylene cannula
(Becton, Dickinson and Company, Sparks, MD, USA)
was threaded subcutaneously at the level of the L5 spinal
process by removing the L5 spinal process and inserting
the tip of the cannula into the subarachnoid space. The
intrathecal infusion lasted for 1 week, after which hind
foot pads were collected for immunohistochemistry.
Data presentation and statistical analyses
All data are presented as group means ± SEM. The data be-
tween db/+ and db/db mice of the same age were analyzed
using the Mann–Whitney test. Statistical comparisons
between different age groups were made by a one-way
ANOVA test followed by a post-hoc Tukey’s multiple
comparison test. A P value of less than 0.05 was consid-
ered statistically significant.
Results
Subepidermal and epidermal CD207-positive LCs in foot
pad skin of db/db mice increase during the period of
mechanical allodynia
To study the LC population in skin during the period
of mechanical allodynia, we performed CD207 immu-
nohistochemistry on foot pad skin of control db/+ and
diabetic db/db mice from 5 to 24 weeks of age.
Figure 1 demonstrates representative confocal images
of CD207 immunohistochemistry from foot pads of
db/+ (Figure 1A,B,C) and db/db mice (Figure 1D,E,F)
at 8 weeks of age. CD207 immunohistochemistry
detected LCs in the epidermal (ELCs, Figure 1, arrows)
and the subepidermal plexus (SLCs, Figure 1, arrow-
heads). Increased numbers of both ELCs and SLCs
were detected in db/db mice compared to db/+ mice
(Figure 1). In addition, CD68 immunohistochemistry,
which labels immature LCs, was performed concomi-
tantly using double immunofluorescence. Strong CD68
immunoreactivity was detected in CD207-positive
SLCs of both db/+ and db/db mice (Figure 1B,E,
arrowheads), with only minimal signal detected in
CD207-positive ELCs (Figure 1B,E, arrows).
Figure 1 Increased quantity of CD207-positive LCs in the epidermis and subepidermal plexus were detected in db/db mice during the
period of mechanical allodynia. Representative double immunofluorescent images of CD207 (green: A,C,D,F) and CD68 (red: B,C,E,F)
immunohistochemistry on hind foot pads from db/+ (A,B,C) and db/db mice (D,E,F) at 8 weeks of age. Increased numbers of CD207-positive
cells in the epidermal Langerhans cells (ELCs, arrows) and subepidermal Langerhans cells (SLCs, arrowheads) were detected in db/db mice
(compare A and D). In contrast, trace CD68 immunoreactivity was observed in ELCs of db/db mice (E, arrows). SLCs were mostly positive for CD68
(B,E, arrowheads). Bar = 50 μm, n = 8. ELC, epidermal Langerhans cell; Epi, epidermis; LC, Langerhans cell; SLC, subepidermal Langerhans cell.
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The LC population increases in skin at 8 to 10 weeks of
age and declines at 16 weeks of age
Quantitative cell density studies at 5 to 24 weeks of age
(Figure 2) demonstrated that increased densities of
CD207-positive SLCs (Figure 2A) and ELCs (Figure 2B)
were detected at 8 to 10 weeks, during the period of
mechanical allodynia. The proliferation of both SLCs
and ELCs subsided after 16 weeks when SLC density
returned to the control level. In contrast, the ELC den-
sity dropped below the control level at 24 weeks of age.
ELCs express Trk A
We next investigated mechanisms for the increase in the
ELC population in db/db mice. LC proliferation could
be triggered by growth factors, cytokines, and chemo-
kines [20]. First, we tested if NGF could be a mitogen
present to mediate LC expansion in db/db mice. We
performed CD207/Trk A double immunohistochemistry
on hind foot pad sections of db/+ (Figure 3A,B,C) and
db/db (Figure 3D,E,F) mice. As demonstrated in
Figure 3, most LCs were positive for Trk A in both
db/+ and db/db mice.
SLCs aggregate along the subepidermal plexus
To examine the cell densities of SLCs within the subepi-
dermal plexus, we performed double immunofluorescent
studies for CD68 and PGP 9.5, a pan-neuronal marker.
PGP 9.5 immunohistochemistry identified intraepi-
dermal nerve fibers (IENFs, arrowheads) and nerve fi-
bers in the subepidermal plexus (Figure 4A,D, asterisks).
Compared to db/+ mice, increased numbers of SLCs
(Figure 4B,C,E,F, arrows) were detected along the sub-
epidermal plexus (compare Figure 4B and E). Most of
these SLCs were also positive for RAGE in db/db
mice (Figure 5E,F, arrowheads), but not in db/+ mice
(Figure 5B,C). In addition, some CD68-negative cells
express RAGE in the subepidermal plexus of db/db
mice (Figure 5E,F, arrows).
Increased SLCs are associated with enhanced TNF-α
expression in the subepidermal plexus
We then investigated the mechanisms that could con-
tribute to the aggregation of LCs in the skin of db/db
mice. We speculated that TNF-α could be a chemotactic
factor that attracts SLCs to the subepidermal plexus. We
performed TNF-α immunohistochemistry. As demon-
strated in Figure 6, TNF-α expression was mostly
detected in the subepidermal plexus and IENFs of db/+
and db/db mice (Figure 6A,C,D,F, arrows). Increased
TNF-α immunoreactivity was detected in db/db mice
compared to db/+ mice (compare Figure 6A and D).
Most of the CD68-positive SLCs were in contact with
TNF-α-positive nerve fibers in db/db mice (Figure 6F).
In addition, some of the CD68-positive cells also
expressed TNF-α immunoreactivity in db/db mice
(Figure 6F, arrowheads).
SB203580 inhibits increased TNF-α expression and
proliferation of CD68-positive SLCs and CD207-positive
ELCs in db/db mice
Previously, we established that NGF/p38 signaling medi-
ates the development of mechanical allodynia in db/db
mice [17]. Using the same approach, we examined the
hypothesis that p38 signaling in dorsal root ganglia
(DRG) mediates increased LC aggregation in skin and
TNF-α expression in the subepidermal plexus of db/db
mice during the period of mechanical allodynia. As de-
scribed previously, we administered control artificial
CSF or SB203580, a p38 inhibitor, via minipumps intra-
thecally for 1 week starting at 7 weeks of age [17]. Foot
pads were collected at the end of the treatment at
8 weeks of age, and processed for CD68 and TNF-α
immunohistochemistry. As demonstrated in Figure 7,
SB203580 significantly reduced the number of CD68-
positive SLCs (compare Figure 7C and D, arrows) and
TNF-α immunoreactivity (compare Figure 7C and D,
arrowheads) in db/db mice. In contrast, SB203580 did
Figure 2 Quantification of CD207-positive LC densities in the subepidermal plexus and epidermis of db/+ and db/db mice during the
time period of mechanical allodynia. (A) Increased densities (cells/mm) of CD207-positive cells were detected in the subepidermal plexus at 8
and 10 weeks of age in db/db mice compared to db/+ mice of the same age. (B) Increased densities of CD207-positive cells were detected in
the epidermal space at 8 and 10 weeks of age in db/db mice compared to db/+ mice of the same age. At 16 weeks, both subepidermal and
epidermal LC densities of db/db mice were reduced to the control levels of db/+ mice. In addition, the epidermal CD207-positive cell densities
were reduced at 24 weeks in db/db mice compared to db/+ mice. **P <0.01, n = 8. LC, Langerhans cell.
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not affect CD68 and TNF-α immunoreactivity in db/+
mice (compare Figure 7A and B). The effect of
SB203580 on the ELC population was studied by CD207
immunohistochemistry (Figure 8). Similar to CD68-
positive SLCs, SB203580 reduced the numbers of
CD207-positive ELCs in db/db mice (compare Figure 8C
and D, arrows), but had no effect in db/+ mice (compare
Figure 8A and B, arrows). Quantification of cell density
revealed a significant reduction of both SLC and ELC
cell densities in db/db mice due to SB203580 treatment
(Figure 9).
Discussion
In the current study, we report the mechanisms of a
novel neurogenic skin inflammation that occurs in PDN
of type 2 diabetes. We detected increased quantities of
LCs in the epidermis and subepidermal plexus in dia-
betic mice during the period of mechanical allodynia.
This inflammatory phenomenon is initiated by p38 sig-
naling in DRG neurons.
Our data suggest increased quantities of ELCs in db/
db mice during the period of mechanical allodynia. In-
creased ELCs have been reported in animal models and
patients with DN. Lauria and colleagues reported in-
creased PGP 9.5-positive LCs in the skin of rats treated
with streptozotocin [23]. A similar phenomenon has
been described in the cornea of patients with DN.
Tavakoli and colleagues reported that increased corneal
LCs correlates with corneal nerve damage in diabetic pa-
tients [24]. The time course of the observed increase in
Figure 4 Increased aggregation of CD68-positive cells in the subepidermal plexus of db/db mice. Representative images of PGP 9.5/CD68
double immunohistochemistry of hind foot pads from db/+ (A,B,C) and db/db (D,E,F) mice at 8 weeks of age. PGP 9.5 immunohistochemistry
demonstrates IENFs (A,D, arrowheads,) and nerve fibers located in the subepidermal nerve plexus (A,C,D,F, asterisks). Increased quantities of
subepidermal CD68-positive cells (B,C,E,F, arrows) were detected in the subepidermal plexus (A,C,D,F, asterisks). Bar = 50 μm, n = 8. Epi, epidermis;
IENF, intraepidermal nerve fiber; PGP, protein gene product.
Figure 3 CD207-positive LCs express Trk A immunoreactivity. Representative images of Trk A/CD207 double immunohistochemistry of hind
foot pads from db/+ (A,B,C) and db/db (D,E,F) mice at 8 weeks of age. Trk A immunoreactivity was detected in both IENFs (A,D, arrows) and
nerve fibers in the subepidermal nerve plexus (A,D, asterisks) in both db/+ and db/db mice. In addition, CD207-positive LCs were positive for Trk
A (B,C,E,F, arrowheads). Most CD207-positive cells also expressed Trk A immunoreactivity in both db/+ (B, arrowheads) and db/db mice (E, arrowheads).
Bar = 50 μm, n = 8. Epi, epidermis; IENF, intraepidermal nerve fiber; LC, Langerhans cell; Trk, tropomyosin-receptor kinase.
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the LC population correlated with the period of me-
chanical allodynia. Consistent with the current study,
Casanova-Molla et al. demonstrated increased LC popula-
tions in skin biopsies of human diabetic subjects with
painful phenotypes [22]. However, the observed increase
in LC populations of painful conditions is not specific to
PDN, as it has also been reported in models of other pain-
ful neuropathies [25] and peripheral nerve injury [26,27].
There are two potential mechanisms for increased LC
populations in foot pad skin of diabetic mice. First, LCs
could proliferate in the epidermis in response to diabetic
conditions [20]. Second, there could be increased recruit-
ment of dermal immature LCs to the epidermis. The
current findings support that both mechanisms coexist.
Our results demonstrate that the expression of Trk A in
epidermal LCs support the first mechanism. The Trk A-
positive LCs could respond to increased NGF from the
nerves at this stage and proliferate. In support of our hy-
pothesis, Noga and colleagues reported that NGF activates
Trk A-positive human monocyte-derived dendritic cells to
mediate asthma [28]. In addition to direct NGF mitogenic
actions on LCs, NGF-dependent factors such as prosta-
glandins, nitric oxide, substance P, calcitonin gene related
peptides, TNF-α, and other cytokines could also contrib-
ute to ELC expansion [17,29-31].
The second proposed mechanism is supported by our
data that demonstrate increased CD68-positive and
CD207-positive cells in the subepidermal plexus during
the period of mechanical allodynia. This mechanism oc-
curs during early embryonic development when imma-
ture LCs migrate out of the bone marrow and distribute
throughout the dermis and the dermal-epidermal
Figure 6 Increased TNF-α expression in the subepidermal plexus of db/db mice. Representative images of TNF-α/CD68 double
immunohistochemistry of hind foot pads from db/+ (A,B,C) and db/db (D,E,F) mice at 8 weeks of age. Increased TNF-α immunoreactivity was
detected in the subepidermal plexus (A,D, arrows), along with increased quantities of subepidermal CD68-positive cells (B,E, arrowheads). Bar = 50 μm,
n = 8. Epi, epidermis.
Figure 5 Subepidermal CD68-positive cells of db/db mice are positive for RAGE. Representative images of CD68/RAGE double
immunohistochemistry of hind foot pads from db/+ (A,B,C) and db/db (D,E,F) mice at 8 weeks of age. RAGE immunoreactivity was only detected
in db/db mice (E, arrowheads) but not db/+ mice (B). Most RAGE-positive cells are positive for CD68 (E, arrowheads) with some exceptions (E, arrow).
Bar = 50 μm, n = 8. Epi = epidermis; RAGE, receptor for advanced glycation end products.
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Figure 8 Intrathecal SB203580 treatment reduces the quantity of CD207-positive cells in the epidermis of db/db mice. Representative
images of CD207 immunohistochemistry of hind foot pads from db/+ (A,B) and db/db (C,D) mice at 8 weeks of age after 1 week of intrathecal
artificial cerebrospinal fluid (CSF) or SB203580 (SB) treatment. Compared to the CSF-treated db/db mice, SB203580 treatment reduced the
quantity of CD207-positive cells in the epidermis (compare C and D, arrows) of the treated db/db mice. In contrast, SB203580 treatment had no
effect on the quantity of CD207-positive cells in the epidermis of db/+ mice (compare A and B). Bar = 50 μm, n = 8. CSF, cerebrospinal fluid;
Epi, epidermis.
Figure 7 Intrathecal SB203580 treatment reduces TNF-α expression and the quantity of CD68-positive cells in the subepidermal plexus
of db/db mice. Representative images of TNF-α/CD68 double immunohistochemistry of hind foot pads from db/+ (A,B) and db/db (C,D) mice at
8 weeks of age after 1 week of intrathecal artificial cerebrospinal fluid (CSF) or SB203580 (SB) treatment. Compared to the CSF-treated db/db
mice, SB203580 treatment reduced the expression of TNF-α in the subepidermal plexus (compare C and D, arrowheads) in the db/db treated
mice. In contrast, SB203580 treatment did not affect TNF-α (arrowheads) or CD68 (arrows) expression in the subepidermal plexus of db/+ mice
(compare A and B). Bar = 50 μm, n = 8. CSF, cerebrospinal fluid; Epi, epidermis.
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junction before they enter the epidermis [32]. Immature
LCs, located in the dermis (identified by CD207-
positivity) are derived from monocytes that are positive
for CD68 [33]. In conditions of dermatitis, similar re-
cruitment of immature LCs and monocytes from bone
marrow to the skin has been reported [33,34]. This ac-
tion is mediated by the CCR2 and CCR6 chemokine re-
ceptors, and colony-stimulating factor-1 signaling
[19,34].
We additionally present data that demonstrate that
CD68-positive and CD207-positive SLCs express RAGE
in db/db mice. This result suggests that diabetes-
induced RAGE expression might contribute to the
increased SLC population in db/db mice. RAGE expres-
sion is important for the homing of maturing dendritic
cells to lymph nodes where they physically interact and
activate T lymphocytes [35]. Thus, it is possible that
RAGE mediates the maturation and migration of SLCs
to the epidermis where they can activate skin immunity,
evidence which further supports the second mechanism.
Additionally, we demonstrate the upregulation of
TNF-α in the subepidermal plexus of diabetic mice.
TNF-α is a cytokine that mediates both acute and
chronic inflammation [36]. Furthermore, increased
TNF-α actions cause neuropathic pain in models of
nerve injury or neuropathy [17,37]. Previously, we
reported that TNF-α is upregulated in DRG neurons in
db/db mice during the period of mechanical allodynia by
a NGF/p38-dependent mechanism [17]. In addition to
PDN, upregulated TNF-α expression was detected in the
skin and muscle nerve afferents by enhanced antero-
grade axonal transport after nerve injury [38,39]. The in-
creased TNF-α level is known to mediate pain by
triggering ectopic activity in afferent sensory nerve fibers
[40,41]. In addition, regional TNF-α administration also
activates LC migration [42], a likely mechanism for in-
creased LC aggregation toward peripheral nerves, as
demonstrated in the current study. The current results
suggest that p38 is an essential mediator for LC-
mediated immunoreaction in PDN of type 2 diabetes.
Previously, we reported that intrathecal SB203580 treat-
ment reduced mechanical allodynia [17] and the
upregulation of IENF densities in db/db mice [43]. Since
SB203580 was administered intrathecally, we can con-
clude that p38 activation in the nervous system contri-
butes to LC aggregation in the skin. Similar neurogenic
inflammation has been reported in other models of
neuropathic pain, including nerve injury by complete or
partial nerve transection and chronic constriction injury
[44]. In the nerve injury model, inflammatory cells such
as macrophages, mast cells, dendritic cells, and Schwann
cells secrete proinflammatory cytokines, chemokines,
growth factors, nitric oxide, and other pain mediators to
enhance neuropathic pain [44]. Along with other re-
searchers in the field, we reported that COX2, TNF-α and
nitric oxide synthases are upregulated by a NGF/p38-
dependent mechanism [17]. However, further studies are
necessary to explore other factors that could contribute to
the development of PDN in type 2 diabetes.
Conclusions
In summary, we detected increased LC populations in the
epidermis and subepidermal plexus of db/db mice during
the period of mechanical allodynia. This phenomenon is
triggered by p38-dependent signaling mechanisms that in-
clude the upregulation of TNF-α in the subepidermal
plexus. Our results support the hypothesis that inhibition
of p38 signaling and/or TNF-α actions could be effective
treatments for PDN.
Abbreviations
AMDCC: Animal models of diabetic complications consortium;
ANOVA: Analysis of variance; COX: Cyclooxygenase; CSF: Cerebrospinal fluid;
DMSO: Dimethyl sulfoxide; DN: Diabetic neuropathy; DRG: Dorsal root
ganglia; ELC: Epidermal langerhans cell; IENF: Intraepidermal nerve fiber;
LC: Langerhans cell; NGF: Nerve growth factor; OCT: Optimal cutting
temperature; PBS: Phosphate buffered saline; PDN: Painful diabetic
neuropathy; PGP: Protein gene product; RAGE: Receptor for advanced
glycation end products; SEM: Standard error of the mean; SLC: Subepidermal
langerhans cell; TNF: Tumor necrosis factor; Trk: Tropomyosin-receptor kinase;
UCUCA: University committee on use and care of animals.
Figure 9 Intrathecal SB203580 treatment reduces LC density in the subepidermal plexus and epidermis of db/db mice. (A) SB203580
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